Sanofi and Regeneron press release on Praluent clinical trial results and pricing

Sanofi and Regeneron press release on Praluent clinical trial results and pricing The passage is a standard pharmaceutical press release describing trial efficacy, safety, pricing, and upcoming regulatory steps. It contains no allegations, financial flows, or connections to high‑profile political or intelligence actors, offering no actionable investigative leads. Key insights: Phase III trial data showing LDL cholesterol reduction with Praluent.; Wholesale Acquisition Cost disclosed at $40 per day.; Announcement of EMA CHMP positive opinion and pending EU approval.